Literature DB >> 17971358

Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients.

S Malik1, G R Bruner, C Williams-Weese, L Feo, R Hal Scofield, M Reichlin, J B Harley, A H Sawalha.   

Abstract

Previous reports suggest a protective role for anti-La autoantibody against the development of lupus nephritis. We studied the effect of anti-La on the prevalence of nephritis in a large cohort of lupus patients. In addition, we determined the association between anti-La and the presence of the various other lupus manifestations. We studied 1100 lupus patients enrolled in the Lupus Family Registry and Repository. Only one lupus patient per family was selected to exclude intrafamilial correlation. Since anti-La is present in patients who also have anti-Ro autoantibody, we compared anti-Ro positive lupus patients in the presence or absence of anti-La. Clinical data were obtained from medical records, interviews and participant questionnaires. Tests for autoantibodies against extractable nuclear antigens were performed using immunodiffussion assays. There is no difference in the age, sex or race between the anti-La positive and anti-La negative lupus patients. The presence of anti-La is associated with a significant reduced risk of lupus nephritis (proteinuria: 29.3% versus 46.3%, OR = 0.48, P = 0.023; cellular casts: 8.6% versus 20.6%, OR = 0.36, P = 0.038). In addition, lupus patients with anti-La have a reduced risk for seizures (0% versus 10.9%, P = 0.0096) and are more likely to have arthritis (79.3% versus 64.0%, OR = 2.16, P = 0.031). The presence of anti-nRNP autoantibody is significantly reduced in anti-La positive compared with anti-La negative lupus patients (10.3% versus 27.4%, OR = 0.31, P = 0.0075). In conclusion, anti-La autoantibody is associated with less severe lupus. Patients with anti-La have a lower risk of renal involvement and seizures compared with anti-La negative lupus patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971358     DOI: 10.1177/0961203307083365

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  15 in total

1.  Do we need new autoantibodies in lupus?

Authors:  R Hal Scofield
Journal:  Arthritis Res Ther       Date:  2010-05-28       Impact factor: 5.156

2.  B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.

Authors:  Lauren L Ritterhouse; Sherry R Crowe; Timothy B Niewold; Joan T Merrill; Virginia C Roberts; Amy B Dedeke; Barbara R Neas; Linda F Thompson; Joel M Guthridge; Judith A James
Journal:  Arthritis Rheum       Date:  2011-12

Review 3.  Lupus nephritis in Colombians: contrasts and comparisons with other populations.

Authors:  Juan-Manuel Anaya; Carlos Cañas; Rubén D Mantilla; Ricardo Pineda-Tamayo; Gabriel J Tobón; Catalina Herrera-Diaz; Diego M Rendón; Adriana Rojas-Villarraga; Mauricio Uribe
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

4.  Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.

Authors:  Sherry R Crowe; Joan T Merrill; Evan S Vista; Amy B Dedeke; David M Thompson; Scott Stewart; Joel M Guthridge; Timothy B Niewold; Beverly S Franek; Gillian M Air; Linda F Thompson; Judith A James
Journal:  Arthritis Rheum       Date:  2011-08

Review 5.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

6.  Epilepsy associated with systemic autoimmune disorders.

Authors:  Orrin Devinsky; Adam Schein; Souhel Najjar
Journal:  Epilepsy Curr       Date:  2013-03       Impact factor: 7.500

7.  Para-Clinical and Immunological Evaluation in Buerger's Disease as a Suspected Autoimmune Disease: Case Series.

Authors:  Abbas Shapouri-Moghaddam; Seyed Jalil Tavakkol Afshari; Hamid Reza Rahimi; Mohammad-Hadi Saeed Modaghegh; Mahmoud Mahmoudi; Seyed Morteza Ehteshamfar
Journal:  Rep Biochem Mol Biol       Date:  2021-01

8.  A novel modular antigen delivery system for immuno targeting of human 6-sulfo LacNAc-positive blood dendritic cells (SlanDCs).

Authors:  Claudia C Bippes; Anja Feldmann; Slava Stamova; Marc Cartellieri; Adrian Schwarzer; Rebekka Wehner; Marc Schmitz; E Peter Rieber; Senming Zhao; Knut Schäkel; Achim Temme; R Hal Scofield; Biji T Kurien; Holger Bartsch; Michael Bachmann
Journal:  PLoS One       Date:  2011-01-21       Impact factor: 3.240

9.  Multiple Autoantibodies Display Association with Lymphopenia, Proteinuria, and Cellular Casts in a Large, Ethnically Diverse SLE Patient Cohort.

Authors:  Rufei Lu; Julie M Robertson; Benjamin F Bruner; Joel M Guthridge; Barbara R Neas; Swapan K Nath; Jennifer A Kelly; Kathy L Moser Sivils; Eliza F Chakravarty; Diane L Kamen; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; R Hal Scofield; John B Harley; Judith A James
Journal:  Autoimmune Dis       Date:  2012-09-04

10.  Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes.

Authors:  Izeta Aganovic-Musinovic; Jasenko Karamehic; Lamija Zecevic; Faris Gavrankapetanovic; Nesina Avdagic; Asija Zaciragic; Tomislav Jukic; Nerima Grcic; Suvada Svrakic
Journal:  Autoimmune Dis       Date:  2012-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.